Akari Therapeutics Plc Quick Ratio (AKTX) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Akari Therapeutics Plc  (NASDAQ: AKTX)

Akari Therapeutics Plc's Quick Ratio

AKTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.25 below Akari Therapeutics Plc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 388 other companies have achieved higher Quick Ratio than Akari Therapeutics Plc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 2771.

Explain Quick Ratio?
How much Cash & cash equivalents AKTX´s has?
What are AKTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKTX Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change -39.44 % -36.11 % 90.3 % 4.81 % 228.97 %
Y / Y Cash & cash equivalent Change 7.2 % - 10.6 % -35.1 % 97.1 %
Quick Ratio MRQ 0.25 0.47 0.17 0.18 0.14
AKTX's Total Ranking # 2771 # 0 # 2383 # 2635 # 2563
Seq. Current Liabilities Change -0.4 % -24.28 % -5.78 % -14.78 % 5.09 %
Seq. Cash & cash equivalent Change -46.8 % 109.46 % -8.37 % 5 % -



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 389
Healthcare Sector # 753
Overall Market # 2771


Quick Ratio Statistics
High Average Low
6.22 2.26 0.12
(Dec 31 2013)   (Mar 31 2025)




Financial Statements
Akari Therapeutics Plc's Current Liabilities $ 11 Millions Visit AKTX's Balance sheet
Akari Therapeutics Plc's Cash & cash equivalent $ 3 Millions Visit AKTX's Balance sheet
Source of AKTX's Sales Visit AKTX's Sales by Geography


Cumulative Akari Therapeutics Plc's Quick Ratio

AKTX's Quick Ratio for the trailling 12 Months

AKTX Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -9.98 % 31.02 % 107.57 % 97.07 % 202.48 %
Y / Y Cash & cash equivalent TTM Growth 46.21 % 67.85 % -32.83 % -24.51 % -52.75 %
Quick Ratio TTM 0.25 0.22 0.12 0.13 0.16
Total Ranking TTM # 3184 # 0 # 3085 # 2856 # 3375
Seq. Current Liabilities TTM Growth -12.09 % -9.53 % 11.81 % 1.23 % 27.95 %
Seq. Cash & cash equivalent TTM Growth 1.43 % 66.9 % 3.16 % -16.28 % 16.45 %

Quick ratio ranking by company, industry and sector >> Back to AKTX Financial Strength Comparisons >> Go to Compare AKTX Quick Ratio to its Competitors

On the trailing twelve months basis AKTX Cash & cash equivalent improved by 7.2 % in Q1 2026 year on year, while Current Liabilities decreased to $11 millions, this led to increase in in Akari Therapeutics Plc's Quick Ratio to 0.25, Quick Ratio remained below AKTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Akari Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 0 to 3184.

Explain Quick Ratio?
How much Cash & cash equivalents AKTX´s has?
What are AKTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 411
Healthcare Sector # 840
Within the Market # 3184


trailing twelve months Quick Ratio Statistics
High Average Low
2.69 1.36 0.14
(Dec 31 2021)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Macrogenics Inc   0.69 $ 66.517  Millions$ 95.940  Millions
Bausch Health Companies Inc   0.67 $ 1,299.000  Millions$ 1,925.000  Millions
Abbott Laboratories  0.67 $ 7,295.000  Millions$ 10,898.000  Millions
Beyondspring Inc   0.65 $ 7.863  Millions$ 12.130  Millions
Cns Pharmaceuticals Inc   0.64 $ 2.951  Millions$ 4.583  Millions
Alaunos Therapeutics Inc   0.59 $ 0.354  Millions$ 0.595  Millions
Biofrontera Inc   0.58 $ 6.317  Millions$ 10.923  Millions
Johnson and Johnson  0.56 $ 22,051.000  Millions$ 39,317.000  Millions
Geovax Labs Inc   0.55 $ 1.272  Millions$ 2.292  Millions
Bristol myers Squibb Company  0.55 $ 10,486.000  Millions$ 19,158.000  Millions
Alzamend Neuro Inc   0.53 $ 0.711  Millions$ 1.346  Millions
Prestige Consumer Healthcare Inc   0.52 $ 63.868  Millions$ 121.657  Millions
Esperion Therapeutics Inc   0.52 $ 156.158  Millions$ 300.359  Millions
Phibro Animal Health Corporation  0.51 $ 77.451  Millions$ 152.474  Millions
Heron Therapeutics Inc   0.49 $ 44.784  Millions$ 90.516  Millions
REST EZ Inc.  0.47 $ 0.009  Millions$ 0.018  Millions
Ainos Inc   0.45 $ 2.841  Millions$ 6.347  Millions
Organon and Co   0.45 $ 1,116.000  Millions$ 2,500.000  Millions
Aytu Biopharma Inc  0.45 $ 26.715  Millions$ 59.972  Millions
Eton Pharmaceuticals Inc   0.45 $ 19.661  Millions$ 44.179  Millions
Earth Science Tech Inc   0.39 $ 0.797  Millions$ 2.029  Millions
Pfizer Inc  0.38 $ 13,075.000  Millions$ 34,348.000  Millions
Jupiter Neurosciences Inc   0.35 $ 2.363  Millions$ 6.723  Millions
Elanco Animal Health Incorporated  0.34 $ 428.000  Millions$ 1,262.000  Millions
Rein Therapeutics Inc   0.33 $ 4.445  Millions$ 13.637  Millions
Cumberland Pharmaceuticals Inc   0.32 $ 11.007  Millions$ 34.488  Millions
Bioxcel Therapeutics Inc   0.31 $ 17.180  Millions$ 54.994  Millions
Cytodyn inc   0.31 $ 15.655  Millions$ 50.428  Millions
Aurinia Pharmaceuticals Inc   0.28 $ 40.749  Millions$ 143.634  Millions
Amneal Pharmaceuticals Inc   0.28 $ 201.830  Millions$ 728.049  Millions

Date modified: 2026-09-26T07:11:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.